1. Home
  2. NUE vs ALNY Comparison

NUE vs ALNY Comparison

Compare NUE & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUE
  • ALNY
  • Stock Information
  • Founded
  • NUE 1905
  • ALNY 2002
  • Country
  • NUE United States
  • ALNY United States
  • Employees
  • NUE N/A
  • ALNY N/A
  • Industry
  • NUE Steel/Iron Ore
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • NUE Industrials
  • ALNY Health Care
  • Exchange
  • NUE Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • NUE 34.5B
  • ALNY 34.7B
  • IPO Year
  • NUE N/A
  • ALNY 2004
  • Fundamental
  • Price
  • NUE $149.56
  • ALNY $249.98
  • Analyst Decision
  • NUE Buy
  • ALNY Buy
  • Analyst Count
  • NUE 7
  • ALNY 23
  • Target Price
  • NUE $190.57
  • ALNY $298.59
  • AVG Volume (30 Days)
  • NUE 2.1M
  • ALNY 958.7K
  • Earning Date
  • NUE 10-21-2024
  • ALNY 10-31-2024
  • Dividend Yield
  • NUE 1.45%
  • ALNY N/A
  • EPS Growth
  • NUE N/A
  • ALNY N/A
  • EPS
  • NUE 10.40
  • ALNY N/A
  • Revenue
  • NUE $31,362,946,000.00
  • ALNY $2,094,795,000.00
  • Revenue This Year
  • NUE N/A
  • ALNY $25.14
  • Revenue Next Year
  • NUE $1.14
  • ALNY $17.13
  • P/E Ratio
  • NUE $14.26
  • ALNY N/A
  • Revenue Growth
  • NUE N/A
  • ALNY 21.54
  • 52 Week Low
  • NUE $133.42
  • ALNY $141.98
  • 52 Week High
  • NUE $203.00
  • ALNY $304.39
  • Technical
  • Relative Strength Index (RSI)
  • NUE 47.17
  • ALNY 40.33
  • Support Level
  • NUE $143.71
  • ALNY $229.86
  • Resistance Level
  • NUE $149.94
  • ALNY $271.08
  • Average True Range (ATR)
  • NUE 4.33
  • ALNY 8.92
  • MACD
  • NUE -0.71
  • ALNY -3.04
  • Stochastic Oscillator
  • NUE 20.49
  • ALNY 34.94

About NUE Nucor Corporation

Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: